Commercialization
-
Sundry Photography via Getty Images
Merck is broadening its pipeline as Keytruda’s patent cliff looms
Merck looks ahead with an array of cardiometabolic, immunology, neuroscience and ophthalmology pipelines.
By Alexandra Pecci • Jan. 14, 2025 -
Stock via Getty Images
The ability to pivot will be ‘key’ as pharma’s tariff threat looms
Companies are looking to new countries like Vietnam for manufacturing needs, but change comes at a cost.
By Kelly Bilodeau • Jan. 13, 2025 -
Stock via Getty Images
Opinion // Year in PreviewPharmaVoice’s Crystal Ball: Industry shifts in R&D, policy and clinical trials
Coming changes that could impact pharma from drug development to launch.
By Meagan Parrish • Jan. 10, 2025 -
Stock via Getty Images
10 of our most read articles of 2024
The high drama of an election year, industry layoffs, patent cliff strategies and other key trends that shaped pharma in 2024.
By Meagan Parrish • Dec. 20, 2024 -
Sarah Silbiger via Getty Images
Zepbound, Mounjaro shortages are resolved, FDA confirms
The FDA’s decision will close a lucrative market opportunity for compounding pharmacies, although the agency will give a limited grace period before taking any enforcement actions.
By Ned Pagliarulo • Dec. 20, 2024 -
Scott Olson via Getty Images
Big Pharma’s new DTC play: partnering with digital health providers
The pharma giant is looking for another edge in the competitive weight loss market through DTC expansion.
By Amy Baxter • Dec. 18, 2024 -
Stock via Getty Images
A drug for fewer than 1,000 patients? Awareness and diagnosis are key.
Zevra Therapeutics is building a commercial strategy for an ultra-small patient pool.
By Amy Baxter • Dec. 9, 2024 -
Permission granted by Alexion/AstraZeneca
How Alexion markets a rare disease drug by ‘starting with the end in mind’
The biopharma, now an arm of AstraZeneca, needs to build the plane while flying it to be first in rare diseases with no other option.
By Michael Gibney • Dec. 3, 2024 -
Permission granted by Ron Tilles, Kevin Mercuri
ProfileLeft to clean up after ‘pharma bro’ Shkreli’s arrest, former Turing CEO Ron Tilles reckons with the past
While Martin Shkreli smirked his way through a public securities fraud investigation, Ron Tilles became interim CEO of Turing Pharmaceuticals, ready or not. Here’s his story.
By Michael Gibney • Nov. 14, 2024 -
Stock via Getty Images
From Mr. Mucus to the Super Bowl, pharma tries offbeat marketing strategies
As the industry’s marketing dollars shift, companies are targeting potential patients in unique ways.
By Amy Baxter • Nov. 13, 2024 -
Permission granted by Pfizer
Pfizer and Lilly’s telehealth prescribing platforms draw Senate scrutiny for ‘potential fraud’
As Big Pharma embraces telehealth to sell medicines directly to patients, lawmakers wonder whether the programs skirt anti-kickback rules.
By Kelly Bilodeau • Nov. 12, 2024 -
Getty Images via Getty Images
Big Pharma earnings hang hope on the next generation of blockbusters
Pfizer, J&J, Biogen and Novartis are banking on new products to make up for maturing blockbusters, but future growth is not guaranteed.
By Michael Gibney • Oct. 31, 2024 -
hapabapa via Getty Images
Backlash builds against Novo’s Catalent takeover
Roche recently joined naysayers who argue the deal threatens competition in the burgeoning weight loss and diabetes drug market.
By Amy Baxter • Oct. 30, 2024 -
Photo illustration: Industry Dive; Getty Images
PharmaVoice 1002024 PharmaVoice 100s: Rare Disease Warriors
Pharma pros driving drug development and access for patients with high unmet needs.
By Meagan Parrish • Oct. 29, 2024 -
Mario Tama via Getty Images
J&J’s comeback kid Spravato heads for blockbuster status
After a slow start, the novel esketamine nasal spray for depression is now J&J’s fastest-growing medication.
By Meagan Parrish • Oct. 25, 2024 -
Buda Mendes via Getty Images
Dengue is spreading and Sanofi is pulling the U.S. market’s only vaccine. What’s next?
As Sanofi prepares to halt production on its dengue vaccine in 2026, locally acquired infections in the U.S. are raising the alarm.
By Alexandra Pecci • Oct. 23, 2024 -
PharmaVoice/PharmaVoice
PharmaVoice 1002024 PharmaVoice 100s: Cardiometabolic All-Stars
Leaders tackling long-standing health needs with new solutions.
By Amy Baxter • Oct. 18, 2024 -
Christopher Furlong via Getty Images
Want to launch a blockbuster? An AstraZeneca exec breaks it down.
Even drugs with “blockbuster potential” often fall short of expectations. Here’s what can help a new medication pass the $1 billion mark.
By Alexandra Pecci • Oct. 16, 2024 -
Courtesy of Madrigal
How Madrigal plans to win on the market with the first MASH drug
Despite the drug’s wide patient pool, Madrigal is taking a targeted approach with its first launch.
By Amy Baxter • Oct. 10, 2024 -
Permission granted by Bluebird bio
Bluebird to lay off another 25% of workforce in latest restructuring
The announced job cuts are the latest in a series of steps Bluebird has taken to preserve cash and break even financially amid slow uptake of its marketed gene therapies.
By Delilah Alvarado • Sept. 25, 2024 -
Stock via Getty Images
Patient access: How Novartis, Eli Lilly, and other Big Pharmas measure up
A new report examines the patient reach efforts of 20 of the world’s largest pharma companies in low- and middle-income countries.
By Alexandra Pecci • Sept. 23, 2024 -
iStock via Getty Images
At J&J, oncology R&D meets commercial strategy in a quest for new standards of care
The disparate teams of research and commercial at J&J work closely together from the get-go.
By Michael Gibney • Sept. 19, 2024 -
George Frey/Reuters
Deep DiveA decade of cancer immunotherapy: Keytruda, Opdivo and the drugs that changed oncology
Over the past 10 years, PD1-blocking medicines have transformed cancer care. But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes.
By Jonathan Gardner • Sept. 10, 2024 -
Getty Images via Getty Images
A new way of determining a drug’s value — with health equity in mind
Quality-adjusted life years are an important tool to frame a drug’s cost effectiveness, but they leave out other determinants of health.
By Michael Gibney • Sept. 10, 2024 -
Sarah Silbiger via Getty Images
FDA adcomm reform talks heat up
As the agency considers eliminating adcomm votes from the approval process, members vie to have their voices heard.
By Amy Baxter • Sept. 3, 2024
